Exercise and type 2 diabetes: Focus on metabolism and inflammation

Immunology and Cell Biology

Volumn 94, Issue 2, 2016, Pages 146-150

  Karstoft, Kristian ^a   Pedersen, Bente Klarlund ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR;

ANTIINFLAMMATORY ACTIVITY; BODY COMPOSITION; CHRONIC INFLAMMATION; DIABETIC PATIENT; EXERCISE; EXERCISE INTENSITY; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS INJURY; PANCREAS ISLET BETA CELL; PHYSICAL ACTIVITY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DIABETES MELLITUS, TYPE 2; IMMUNOLOGY; INFLAMMATION; KINESIOTHERAPY; METABOLISM; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; EXERCISE; EXERCISE THERAPY; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84983188112     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2015.101     Document Type: Review

References (64)

1. IDF Diabetes Atlas, 6th edn, 2013, www.idf.org/diabetesatlas.
2. Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract 2014; 103: 150-160.
3. Moe B, Eilertsen E, Nilsen TI. The combined effect of leisure-time physical activity and diabetes on cardiovascular mortality: the Nord-Trondelag Health (HUNT) cohort study, Norway. Diabetes Care 2013; 36: 690-695.
4. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008; 117: 1945-1954.
5. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
6. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37 (Suppl 1): S14-S80.
7. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-3087.
8. Pedersen BK. The diseasome of physical inactivity-and the role of myokines in muscle-fat cross talk. J Physiol 2009; 587: 5559-5568.
9. Knudsen SH, Pedersen BK. Targeting inflammation through a physical active lifestyle and pharmaceuticals for the treatment of type 2 diabetes. Curr Diab Rep 2015; 15: 82.
10. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.
11. Scheen AJ, Esser N, Paquot N. Antidiabetic agents: potential anti-inflammatory activity beyond glucose control. Diabetes Metab 2015; 41: 183-194.
12. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 2014; 13: 465-476.
13. Westwell-Roper CY, Ehses JA, Verchere CB. Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1beta production and beta-cell dysfunction. Diabetes 2014; 63: 1698-1711.
14. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
15. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245: 621-625.
16. Benatti FB, Pedersen BK. Exercise as an anti-inflammatory therapy for rheumatic diseases-myokine regulation. Nat Rev Rheumatol 2015; 11: 86-97.
17. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005; 54: 2939-2945.
18. Pedersen BK, Febbraio MA. Point: Interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol (1985) 2007; 102: 814-816.
19. Umpierre D, Ribeiro PA, Kramer CK, Leitao CB, Zucatti AT, Azevedo MJ et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 2011; 305: 1790-1799.
20. Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care 2006; 29: 2518-2527.
21. Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA 2010; 304: 2253-2262.
22. Sigal RJ, Kenny GP, Boule NG, Wells GA, Prud'homme D, Fortier M et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 2007; 147: 357-369.
23. Balducci S, Zanuso S, Nicolucci A, De FP, Cavallo S, Cardelli P et al. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med 2010; 170: 1794-1803.
24. Tanasescu M, Leitzmann MF, Rimm EB, Hu FB. Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation 2003; 107: 2435-2439.
25. Holten MK, Zacho M, Gaster M, Juel C, Wojtaszewski JF, Dela F. Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. Diabetes 2004; 53: 294-305.
26. Castaneda C, Layne JE, Munoz-Orians L, Gordon PL, Walsmith J, Foldvari M et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 2002; 25: 2335-2341.
27. Kirk A, Mutrie N, MacIntyre P, Fisher M. Increasing physical activity in people with type 2 diabetes. Diabetes Care 2003; 26: 1186-1192.
28. Taylor JD, Fletcher JP, Tiarks J. Impact of physical therapist-directed exercise counseling combined with fitness center-based exercise training on muscular strength and exercise capacity in people with type 2 diabetes: a randomized clinical trial. Phys Ther 2009; 89: 884-892.
29. Praet SF, van Rooij ES, Wijtvliet A, Boonman-de Winter LJ, Enneking T, Kuipers H et al. Brisk walking compared with an individualised medical fitness programme for patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2008; 51: 736-746.
30. Tudor-Locke C, Bell RC, Myers AM, Harris SB, Ecclestone NA, Lauzon N et al. Controlled outcome evaluation of the First Step Program: a daily physical activity intervention for individuals with type II diabetes. Int J Obes Relat Metab Disord 2004; 28: 113-119.
31. Umpierre D, Ribeiro PA, Schaan BD, Ribeiro JP. Volume of supervised exercise training impacts glycaemic control in patients with type 2 diabetes: a systematic review with meta-regression analysis. Diabetologia 2013; 56: 242-251.
32. Albright A, Franz M, Hornsby G, Kriska A, Marrero D, Ullrich I et al. American College of Sports Medicine position stand. Exercise and type 2 diabetes. Med Sci Sports Exerc 2000; 32: 1345-1360.
33. Perri MG, Anton SD, Durning PE, Ketterson TU, Sydeman SJ, Berlant NE et al. Adherence to exercise prescriptions: effects of prescribing moderate versus higher levels of intensity and frequency. Health Psychol 2002; 21: 452-458.
34. Hansen D, Dendale P, Jonkers RA, Beelen M, Manders RJ, Corluy L et al. Continuous low-to moderate-intensity exercise training is as effective as moderate-to high-intensity exercise training at lowering blood HbA(1c) in obese type 2 diabetes patients. Diabetologia 2009; 52: 1789-1797.
35. Balducci S, Zanuso S, Cardelli P, Salvi L, Bazuro A, Pugliese L et al. Effect of highversus low-intensity supervised aerobic and resistance training on modifiable cardiovascular risk factors in type 2 diabetes; the Italian Diabetes and Exercise Study (IDES). PLoS ONE 2012; 7: e49297.
36. Manders RJ, Van Dijk JW, van Loon LJ. Low-intensity exercise reduces the prevalence of hyperglycemia in type 2 diabetes. Med Sci Sports Exerc 2010; 42: 219-225.
37. DiPietro L, Dziura J, Yeckel CW, Neufer PD. Exercise and improved insulin sensitivity in older women: evidence of the enduring benefits of higher intensity training. J Appl Physiol 2006; 100: 142-149.
38. Tjonna AE, Lee SJ, Rognmo O, Stolen TO, Bye A, Haram PM et al. Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study. Circulation 2008; 118: 346-354.
39. Mitranun W, Deerochanawong C, Tanaka H, Suksom D. Continuous vs interval training on glycemic control and macro-and microvascular reactivity in type 2 diabetic patients. Scand J Med Sci Sports 2013; 24: e69-e76.
40. Robinson E, Durrer C, Simtchouk S, Jung ME, Bourne JE, Voth E et al. Short-term high-intensity interval and moderate-intensity continuous training reduce leukocyte TLR4 in inactive adults at elevated risk of type 2 diabetes. J Appl Physiol (1985) 2015; 119: 508-516.
41. Karstoft K, Winding K, Knudsen SH, Nielsen JS, Thomsen C, Pedersen BK et al. The effects of free-living interval-walking training on glycemic control, body composition, and physical fitness in type 2 diabetes patients. Diabetes Care 2013; 36: 228-236.
42. Karstoft K, Winding K, Knudsen SH, James NG, Scheel MM, Olesen J et al. Mechanisms behind the superior effects of interval vs continuous training on glycaemic control in individuals with type 2 diabetes: a randomised controlled trial. Diabetologia 2014; 57: 2081-2093.
43. Karstoft K, Christensen CS, Pedersen BK, Solomon TP. The acute effects of interval-vs. continuous-walking exercise on glycemic control in subjects with type 2 diabetes: a cross-over, controlled study. J Clin Endocrinol Metab 2014; 99: 3334-3342.
44. Francois ME, Baldi JC, Manning PJ, Lucas SJ, Hawley JA, Williams MJ et al. 'Exercise snacks' before meals: a novel strategy to improve glycaemic control in individuals with insulin resistance. Diabetologia 2014; 57: 1437-1445.
45. Lunt H, Draper N, Marshall HC, Logan FJ, Hamlin MJ, Shearman JP et al. High intensity interval training in a real world setting: a randomized controlled feasibility study in overweight inactive adults, measuring change in maximal oxygen uptake. PLoS ONE 2014; 9: e83256.
46. Bortoluzzi S, Scannapieco P, Cestaro A, Danieli GA, Schiaffino S. Computational reconstruction of the human skeletal muscle secretome. Proteins 2006; 62: 776-792.
47. Yoon JH, Yea K, Kim J, Choi YS, Park S, Lee H et al. Comparative proteomic analysis of the insulin-induced L6 myotube secretome. Proteomics 2009; 9: 51-60.
48. Henningsen J, Rigbolt KT, Blagoev B, Pedersen BK, Kratchmarova I. Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol Cell Proteomics 2010; 9: 2482-2496.
49. Pedersen BK, Fischer CP. Physiological roles of muscle-derived interleukin-6 in response to exercise. Curr Opin Clin Nutr Metab Care 2007; 10: 265-271.
50. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008; 88: 1379-1406.
51. Whitham M, Chan MH, Pal M, Matthews VB, Prelovsek O, Lunke S et al. Contractioninduced interleukin-6 gene transcription in skeletal muscle is regulated by c-Jun terminal kinase/activator protein-1. J Biol Chem 2012; 287: 10771-10779.
52. Helge JW, Stallknecht B, Pedersen BK, Galbo H, Kiens B, Richter EA. The effect of graded exercise on IL-6 release and glucose uptake in human skeletal muscle. J Physiol 2003; 546: 299-305.
53. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 2003; 17: 884-886.
54. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesityassociated resistance to insulin. Nat Immunol 2014; 15: 423-430.
55. Ellingsgaard H, Ehses JA, Hammar EB, Van LL, Quintens R, Martens G et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci USA 2008; 105: 13163-13168.
56. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011; 17: 1481-1489.
57. Munoz-Canoves P, Scheele C, Pedersen BK, Serrano AL. Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword FEBS J 2013; 280: 4131-4148.
58. Yudkin JS. Inflammation, obesity, and the metabolic syndrome. Horm Metab Res 2007; 39: 707-709.
59. Olsen RH, Krogh-Madsen R, Thomsen C, Booth FW, Pedersen BK. Metabolic responses to reduced daily steps in healthy nonexercising men. JAMA 2008; 299: 1261-1263.
60. Rinnov A, Yfanti C, Nielsen S, Akerstrom TC, Peijs L, Zankari A et al. Endurance training enhances skeletal muscle interleukin-15 in human male subjects. Endocrine 2014; 45: 271-278.
61. Pedersen BK. Muscle as a secretory organ. Compr Physiol 2013; 3: 1337-1362.
62. Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell 2014; 157: 1279-1291.
63. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012; 8: 457-465.
64. Lee DC, Sui X, Artero EG, Lee IM, Church TS, McAuley PA et al. Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: the Aerobics Center Longitudinal Study. Circulation 2011; 124: 2483-2490.